Prospective Trial Data on MRD Testing in Early-Stage CRC

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Data from FRESCO-2 support the approval of fruquintinib for those with previously treated metastatic colorectal cancer in the European Union.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.